Understanding Serum Proinsulin: A Key Biomarker for Beta-Cell Health in Diabetes

Diabetes mellitus, affecting over 530 million adults worldwide, is characterized by defective insulin secretion, insulin resistance, or both. At the core of this disease lies the pancreatic beta-cell — the only cell type capable of producing and secreting insulin in response to glucose. As beta-cell function deteriorates, blood glucose rises, leading to progressive disease. For decades, clinicians and researchers have sought reliable biomarkers that can non-invasively assess the functional status of these cells. Among the candidates, serum proinsulin has gained significant attention. Unlike insulin or C-peptide alone, proinsulin levels provide a window into the secretory machinery of the beta-cell and its state of stress. This article explores the biology of proinsulin, its role as a biomarker, clinical applications, and the evidence supporting its use in diabetes management.

What Is Serum Proinsulin?

Proinsulin is the single-chain precursor molecule from which insulin and C-peptide are derived. It is synthesized in the rough endoplasmic reticulum of pancreatic beta-cells and then transported to the Golgi apparatus, where it is packaged into secretory vesicles. Inside these vesicles, specific proteases — prohormone convertases 1/3 and 2 — cleave proinsulin to yield equimolar amounts of mature insulin and C-peptide. Under normal physiologic conditions, only a small fraction (<5%) of the proinsulin is released into the circulation without complete processing. However, when beta-cells are under stress — due to increased demand, glucotoxicity, lipotoxicity, or genetic defects — the processing machinery can become overwhelmed or impaired, leading to a disproportionate release of intact or partially processed proinsulin into the bloodstream.

Molecular Structure and Processing

Proinsulin consists of three peptides: the B-chain, C-peptide, and A-chain, linked together by the connecting peptide (C-peptide) region. The complete molecule has a molecular weight of approximately 9,000 daltons. The conversion to insulin requires precise cleavage at dibasic amino acid residues, a process that is highly regulated and dependent on intracellular pH and calcium. In a healthy beta-cell, this processing is efficient, resulting in a low proinsulin-to-insulin ratio. In states of beta-cell dysfunction, the ratio rises. It is this elevation in serum proinsulin — either absolute or relative to insulin or C-peptide — that forms the basis for its use as a biomarker.

Why Measure Proinsulin? The Rationale for a Beta-Cell Stress Marker

Traditional markers of beta-cell function include fasting insulin, C-peptide, and glucose-stimulated insulin secretion during oral glucose tolerance tests. While these markers provide information about the quantity of insulin produced, they do not directly reflect the quality of insulin secretion or the secretory health of the beta-cell. Elevated proinsulin levels indicate that beta-cells are struggling to process their principal product. This finding is particularly valuable in the early stages of type 2 diabetes, where beta-cell dysfunction often precedes overt hyperglycemia.

Proinsulin vs. C-Peptide: Complementary Information

C-peptide is secreted in equimolar amounts with insulin and is a stable indicator of insulin production, especially when using certain assays. However, C-peptide does not reveal the efficiency of proinsulin processing. High C-peptide levels can occur even when a large portion of the secreted output is incompletely processed proinsulin. Measuring proinsulin adds a dimension of secretory quality. For example, in patients with type 2 diabetes, C-peptide may appear sufficient while proinsulin levels are disproportionately high, signaling beta-cell stress. In type 1 diabetes, a similar pattern can be seen in the “honeymoon” period when residual beta-cells are under attack. Thus, the proinsulin-to-C-peptide ratio is a sensitive indicator of impending beta-cell failure.

Research Findings: Evidence Supporting Proinsulin as a Biomarker

Multiple large-scale studies have confirmed the association between elevated serum proinsulin and the development and progression of diabetes. The Insulin Resistance Atherosclerosis Study (IRAS) demonstrated that higher proinsulin levels were independent predictors of future type 2 diabetes, even after adjusting for obesity and insulin resistance. Similarly, data from the Whitehall II study and the Framingham Offspring Study showed that individuals in the highest quartile of proinsulin had a two- to threefold increased risk of developing diabetes over follow-up periods of 5–11 years.

Proinsulin and Beta-Cell Dysfunction in Type 2 Diabetes

In established type 2 diabetes, elevated proinsulin correlates with lower beta-cell function as assessed by the homeostasis model assessment of beta-cell function (HOMA-B) and the insulin secretory response to oral glucose. A meta-analysis published in Diabetologia (2015) reported that the proinsulin-to-insulin ratio increases progressively from normal glucose tolerance to impaired glucose tolerance and then to diabetes, with each stage showing a stepwise rise. Importantly, the ratio predicts the conversion from prediabetes to diabetes, offering a window for early intervention.

Proinsulin in Type 1 Diabetes: A Marker of Residual Mass

In type 1 diabetes, C-peptide is the traditional marker of residual beta-cell function, with sustained endogenous insulin production associated with fewer complications. However, studies have shown that even when C-peptide is detectable, the proinsulin-to-C-peptide ratio is often elevated, indicating that the remaining beta-cells are under immune-mediated stress. A study by Watkins et al. found that in new-onset type 1 diabetes patients, higher proinsulin levels correlated with a more rapid decline in residual beta-cell function over the following year. This suggests that proinsulin can serve as a prognostic marker in type 1 diabetes, potentially identifying individuals who may benefit from immune intervention therapies.

Proinsulin in Gestational Diabetes and Obesity

Elevated proinsulin levels are also observed in gestational diabetes mellitus (GDM) and in obese individuals without diabetes. In GDM, increased proinsulin reflects the inability of beta-cells to meet the heightened insulin demands of pregnancy, and it predicts the later development of type 2 diabetes. In obesity, chronically elevated proinsulin levels may indicate subclinical beta-cell stress even before glucose tolerance becomes abnormal. This makes proinsulin a potential screening tool for identifying high-risk individuals in populations with metabolic syndrome.

Clinical Implications: How Proinsulin Can Guide Diabetes Management

The integration of serum proinsulin measurement into clinical practice holds promise for several key areas: early detection, risk stratification, monitoring disease progression, and evaluating therapeutic efficacy.

Early Detection of Beta-Cell Dysfunction

Because proinsulin elevation can precede hyperglycemia, it may allow earlier identification of individuals at risk for diabetes. In primary care, adding proinsulin to routine metabolic panels could flag patients who are metabolically decompensating even when fasting glucose and HbA1c are still within normal ranges. For instance, an otherwise healthy individual with obesity and a family history of diabetes who shows an elevated fasting proinsulin level may be counseled to adopt lifestyle modifications to preserve beta-cell function.

Monitoring Disease Progression and Treatment Response

Once diabetes is diagnosed, serial measurement of proinsulin can track the decline or stabilization of beta-cell function. In patients with type 2 diabetes on glucose-lowering therapies, a rising proinsulin-to-C-peptide ratio may indicate that the current regimen is not protecting beta-cell health and that more aggressive intervention is needed. Some oral agents, such as GLP-1 receptor agonists and DPP-4 inhibitors, have been shown to improve proinsulin processing in clinical trials. For example, a study on liraglutide published in Diabetes Care found that treatment reduced the proinsulin-to-insulin ratio compared to placebo, suggesting improved beta-cell function. Monitoring proinsulin could thus help clinicians assess whether a therapy is genuinely benefiting the beta-cell or merely compensating for its dysfunction.

Prognosis in Type 1 Diabetes

In type 1 diabetes, proinsulin levels may indicate the durability of residual beta-cell function. Patients with lower proinsulin-to-C-peptide ratios at diagnosis tend to maintain detectable C-peptide for longer, which is associated with lower HbA1c, reduced risk of severe hypoglycemia, and lower rates of long-term complications. Clinical trials of immunomodulatory therapies (e.g., teplizumab) now use proinsulin as a secondary endpoint, alongside C-peptide, to assess whether treatment preserves the function of remaining beta-cells. The Type 1 Diabetes TrialNet studies have incorporated proinsulin measures, and early results indicate that proinsulin is a sensitive indicator of treatment effects.

Assay Standardization and Practical Considerations

Despite its promise, clinical adoption of proinsulin measurement faces challenges. Historically, proinsulin assays have suffered from cross-reactivity with insulin and C-peptide, leading to variable results. Modern immunometric assays using specific monoclonal antibodies have largely resolved this issue, but standardization across laboratories remains incomplete. The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) is working on an international reference material to harmonize results. Additionally, proinsulin is unstable at room temperature and degrades over time; plasma samples must be processed and stored at -80°C for research purposes, though clinical samples can be analyzed with appropriate handling protocols.

Reference Ranges and Interpretation

Establishing normal ranges for serum proinsulin is complicated by age, sex, and body composition. Fasting proinsulin levels in healthy individuals are typically below 5–10 pmol/L, but vary by assay. The proinsulin-to-insulin ratio is generally below 0.2 in normal glucose tolerance. Clinicians must interpret results in the context of the specific assay used and the patient’s glycemic status. It is also important to consider that renal impairment can cause proinsulin accumulation, as it is cleared partly by the kidneys. Conditions such as insulinoma can also elevate proinsulin, although this is rare. For most diabetes patients, monitoring trends over time is more informative than a single measurement.

Future Directions and Emerging Research

Research continues to refine the utility of proinsulin in diabetes care. Novel areas of investigation include the use of proinsulin as a marker for beta-cell dedifferentiation, a process in which beta-cells lose their identity and stop producing insulin. This phenomenon is thought to be reversible and may explain some cases of apparent “recovery” of beta-cell function after bariatric surgery or intensive glucose control. Studies using paired pancreas biopsies and proinsulin measurements in serum are beginning to validate these concepts. Additionally, the development of mass spectrometry-based assays that can distinguish intact proinsulin from specific processing intermediates (split products) may provide even more granular metabolic information.

Proinsulin in Diabetes Prevention Trials

Proinsulin is being explored as a surrogate endpoint in diabetes prevention studies. For example, the Diabetes Prevention Program (DPP) measured proinsulin levels and found that lifestyle intervention and metformin both reduced the proinsulin-to-insulin ratio compared to placebo, consistent with improved beta-cell function. Such findings suggest that proinsulin can be used to assess the effect of preventive interventions in high-risk populations.

Integration with Other Biomarkers

Combining proinsulin with other markers — such as branched-chain amino acids, triglycerides, or inflammatory markers like IL-6 — could create a multi-marker panel for diabetes risk assessment. Machine learning algorithms that incorporate proinsulin along with genetic and clinical data may improve prediction models for beta-cell failure. The cost-effectiveness of adding proinsulin to routine screening panels will need to be evaluated, but given its potential to identify dysfunction early, it may ultimately reduce the long-term burden of diabetes complications.

Limitations and Caveats

No biomarker is perfect. Proinsulin measurement is not yet standardized across all clinical labs, and its interpretation can be confounded by factors such as renal function, the presence of insulin antibodies, and heterophilic antibody interference in immunoassays. Furthermore, the relationship between proinsulin and beta-cell health is not purely linear: in some settings, such as after initiation of insulin therapy in type 2 diabetes, proinsulin levels may initially fall as glucose toxicity is relieved, then rise again as the disease progresses. Clinicians must combine proinsulin results with other clinical data, including HbA1c, glucose levels, and the clinical history of the patient.

Conclusion

Serum proinsulin is a powerful and increasingly validated biomarker for beta-cell dysfunction across the spectrum of diabetes. Its ability to reflect secretory stress and processing inefficiency offers insights that insulin and C-peptide alone cannot provide. From early prediction of type 2 diabetes to monitoring residual function in type 1 diabetes, proinsulin has the potential to enhance clinical decision-making and improve patient outcomes. As assay standardization advances and more longitudinal data become available, the adoption of proinsulin in routine practice is likely to grow. For clinicians and researchers alike, understanding proinsulin biology opens a new window into the health of the pancreatic beta-cell — a key to changing the trajectory of the diabetes epidemic.

For further reading, see the clinical practice guidelines on beta-cell function from the American Diabetes Association, the review article on proinsulin as a biomarker in Diabetes Care (available here), and the latest research from the National Institute of Diabetes and Digestive and Kidney Diseases.